Provet Cloud vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Information Management System
Cloud-based veterinary information management system acquired by Nordhealth; Helsinki Finland; serves 3,000+ clinics across Europe, Australia, New Zealand, and North America;
About
Provet Cloud is a cloud-based veterinary information management system (VIMS) that provides veterinary practices with patient records, appointment scheduling, invoicing, pharmacy management, lab integration, and reporting in a browser-accessible platform, developed and headquartered in Helsinki, Finland and acquired by Nordhealth, the Nordic health technology group. Provet Cloud serves more than 3,000 veterinary clinics across Europe, Australia, New Zealand, and North America, making it one of the most internationally deployed cloud-native veterinary practice management platforms available.\n\nProvet Cloud's platform is designed for general veterinary practices, emergency clinics, and specialty hospitals, offering a clinical workflow that tracks patients from check-in through consultation, diagnostics, treatment, and discharge with integrated invoicing and payment collection. Lab integrations connect directly to in-house analyzers and external diagnostic labs, bringing results into the patient record automatically. The platform's multi-location and multi-user architecture supports corporate veterinary groups and franchise networks that need consolidated reporting across clinics while maintaining individual clinic workflows. APIs allow integration with third-party diagnostic, imaging, and practice growth tools.\n\nAs part of Nordhealth, Provet Cloud benefits from investment in development resources and synergies with Nordhealth's other healthcare technology platforms. Provet Cloud competes with ezyVet (owned by IDEXX), Digitail, Vetspire, and the legacy PIMS offerings from IDEXX and Henry Schein. Its strong presence in European and Australasian markets differentiates it from US-centric competitors, and its API-first architecture appeals to technology-forward practices and corporate groups building integrated technology stacks.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.